Phase II LAPACT trial of <i>nab</i>-paclitaxel (<i>nab</i>-P) plus gemcitabine (G) for patients with locally advanced pancreatic cancer (LAPC).
Pascal Hammel(Hôpital Paul-Brousse), Philip Agop Philip(Wayne State University), Jill Lacy(Smilow Cancer Hospital), Teng Jin Ong, R.A. Pazo Cid(Hospital Universitario Miguel Servet), Alberto F. Sobrero(Ospedale Policlinico San Martino), Jack Shiansong Li, Scot Dowden, José Luis Manzano Mozo(Sorbonne Université), Thom Nydam, Fabienne Portales(Institut de Recherche en Cancérologie de Montpellier), Eric Terrebonne(Hôpital Cardiologique du Haut-Lévêque)
Cited by 32
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
|New England Journal of Medicine|2018|2.9k
FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis
|The Lancet Oncology|2016|914
Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
|JAMA Oncology|2022|336
Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis
|JNCI Journal of the National Cancer Institute|2019|299